Clinical Trials › NCT05285891
RecruitingPhase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 123
Target enrollment
9
U.S. states
Jan 2023
Start date
Nov 2030
Expected completion
Interventions / Treatments
OcrelizumabPlacebo for Ocrelizumab
Conditions studied
Multiple Sclerosis
Where this trial is running (12 sites)
Massachusetts2 sites
Boston · Worcester
New York2 sites
New York · Rochester
Texas2 sites
Dallas · Houston
Connecticut1 site
New Haven
District of Columbia1 site
Washington D.C.
Illinois1 site
Chicago
Oklahoma1 site
Oklahoma City
Pennsylvania1 site
Philadelphia
Virginia1 site
Richmond
Participating MS centers on MS Buddy (9)
OMRF Multiple Sclerosis Center of Excellence
Oklahoma City, OK
Oklahoma City, OK
Georgetown Multiple Sclerosis and Neuroimmunology Center
Washington, DC
Washington, DC
UMass Memorial Medical Center MS Clinic
Worcester, MA
Worcester, MA
Massachusetts General Hospital MS Clinic
Boston, MA
Boston, MA
Rochester Multiple Sclerosis Center
Rochester, NY
Rochester, NY
MS centers in Massachusetts
Compare treatment centers near a trial site by center type, providers and trials.
View Massachusetts centersMore Phase 4 trials
Browse all Phase 4 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.